BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36793790)

  • 1. Evaluation the effectiveness of the Jiangniaosuan formulation in the treatment of hyperuricemic nephropathy in patients with chronic kidney disease stages 3-4: Study protocol of a randomized controlled trial.
    Lu L; Xu L; He Y; Shen J; Xin J; Zhou J; Wang C; Wang Y; Pan X; Gao J
    Contemp Clin Trials Commun; 2023 Apr; 32():101065. PubMed ID: 36793790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Chinese herbal medicine Jiangniaosuan formula for treatment of hyperuricemia: study protocol for a double-blinded non-inferiority randomized controlled clinical trial.
    Guo Y; Lu H; Gan J; Li D; Gao J; Zhang C
    Trials; 2022 Jan; 23(1):1. PubMed ID: 34980237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
    Tanaka K; Nakayama M; Kanno M; Kimura H; Watanabe K; Tani Y; Hayashi Y; Asahi K; Terawaki H; Watanabe T
    Clin Exp Nephrol; 2015 Dec; 19(6):1044-53. PubMed ID: 25676011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S; Li JP
    Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial.
    Stack AG; Dronamraju N; Parkinson J; Johansson S; Johnsson E; Erlandsson F; Terkeltaub R
    Am J Kidney Dis; 2021 Apr; 77(4):481-489. PubMed ID: 33130235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy.
    Beddhu S; Filipowicz R; Wang B; Wei G; Chen X; Roy AC; DuVall SL; Farrukh H; Habib AN; Bjordahl T; Simmons DL; Munger M; Stoddard G; Kohan DE; Greene T; Huang Y
    Can J Kidney Health Dis; 2016; 3():2054358116675343. PubMed ID: 28270924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study.
    Osonoi T; Saito M; Hosoya M; Douguchi S; Ofuchi K; Katoh M
    Front Endocrinol (Lausanne); 2022; 13():1042061. PubMed ID: 36714585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Chuan Huang Fang Combining Reduced Glutathione in Treating Acute Kidney Injury (Grades 1-2) on Chronic Kidney Disease (Stages 2-4): Study Protocol for a Multicenter Randomized Controlled Clinical Trial.
    Chen L; Gong X
    Evid Based Complement Alternat Med; 2022; 2022():1099642. PubMed ID: 35341156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjects with hyperuricemia.
    Pingali U; Nutalapati C; Koilagundla N; Taduri G
    BMC Complement Med Ther; 2020 Sep; 20(1):281. PubMed ID: 32933504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
    Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
    Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout.
    Hosoya T; Ohno I; Nomura S; Hisatome I; Uchida S; Fujimori S; Yamamoto T; Hara S
    Clin Exp Nephrol; 2014 Dec; 18(6):876-84. PubMed ID: 24448692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Keluoxin capsule combined with losartan potassium on diabetic kidney disease: study protocol for a randomized double-blind placebo-controlled multicenter clinical trial.
    Wu R; Wei F; Qu L; Bai L; Li J; Li F; Yan W; Wang Q; Wei J
    Trials; 2020 Nov; 21(1):951. PubMed ID: 33228726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Traditional Chinese Medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: A structured summary of a study protocol for a randomized controlled trial.
    Zeng C; Yuan Z; Pan X; Zhang J; Zhu J; Zhou F; Shan Z; Yuan Y; Ye R; Cheng J
    Trials; 2020 Dec; 21(1):1029. PubMed ID: 33357239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The key role of Shenyan Kangfu tablets, a Chinese patent medicine for diabetic nephropathy: study protocol for a randomized, double-blind and placebo-controlled clinical trial.
    Wang H; Mu W; Zhai J; Xing D; Miao S; Wang J; Deng Y; Wang N; Chen H; Yang H; He X; Shang H
    Trials; 2013 Jun; 14():165. PubMed ID: 23738508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of traditional chinese medicine (Shenqi particle) for patients with idiopathic membranous nephropathy: a multicenter randomized controlled clinical trial.
    Chen Y; Deng Y; Ni Z; Chen N; Chen X; Shi W; Zhan Y; Yuan F; Deng W; Zhong Y
    Am J Kidney Dis; 2013 Dec; 62(6):1068-76. PubMed ID: 23810688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial.
    Li P; Chen YZ; Lin HL; Ni ZH; Zhan YL; Wang R; Yang HT; Fang JA; Wang NS; Li WG; Sun XF; Chen XM
    Trials; 2017 Apr; 18(1):170. PubMed ID: 28395659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chinese herbal medicine Shenzhuo Formula treatment in patients with macroalbuminuria secondary to diabetic kidney disease: study protocol for a randomized controlled trial.
    Zhao XM; Zhang Y; He XH; Chen HD; Wang ZF; Guo J; Wang XM; Gao ZZ; Wang JP; Liu W; Zhao LH; Tong XL
    Trials; 2018 Mar; 19(1):200. PubMed ID: 29587863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation analysis of renal ultrasound elastography and clinical and pathological changes in patients with chronic kidney disease
.
    Peng L; Zhong T; Fan Q; Liu Y; Wang X; Wang L
    Clin Nephrol; 2017 Jun; 87(6):293-300. PubMed ID: 28332473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
    Sircar D; Chatterjee S; Waikhom R; Golay V; Raychaudhury A; Chatterjee S; Pandey R
    Am J Kidney Dis; 2015 Dec; 66(6):945-50. PubMed ID: 26233732
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.